ArticleDelaware journal of public health2026
Recent Advances in Modeling and Prediction of Blood Glucose in Type 1 Diabetes.
Article in Delaware journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate prediction and control of blood glucose levels are essential for the management of type 1 diabetes, where patients rely on exogenous insulin and are vulnerable to both hypoglycemia and hyperglycemia. The widespread adoption of continuous glucose monitoring systems, insulin pumps, and wearable devices has generated large volumes of physiological and behavioral data, creating new opportunities for computational modeling and intelligent decision support. This review surveys recent advances in glucose prediction and control models, with a primary focus on type 1 diabetes. We examine three major classes of approaches: mechanistic models based on physiological principles, data-driven machine learning methods, and hybrid or biology-informed frameworks that integrate mechanistic knowledge with learning-based techniques. We also discuss the growing role of multimodal data, deep learning architectures, and reinforcement learning for automated insulin dosing and adaptive control in artificial pancreas systems. Despite significant progress, important challenges remain, including handling noisy and heterogeneous data, improving predictive reliability and uncertainty quantification, and enabling real-time deployment on resource-constrained medical devices. Emerging strategies such as edge computing, efficient model design, and hardware-algorithm co-optimization may help bridge this gap. Continued progress will require interdisciplinary collaboration, standardized evaluation on public datasets, and rigorous clinical validation to translate emerging modeling approaches into practical tools that improve patient outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.